www.lightstonevc.com
Open in
urlscan Pro
173.199.178.36
Public Scan
Effective URL: https://www.lightstonevc.com/
Submission: On October 17 via api from US — Scanned from DE
Summary
TLS certificate: Issued by R3 on September 20th 2022. Valid for: 3 months.
This is the only time www.lightstonevc.com was scanned on urlscan.io!
urlscan.io Verdict: No classification
Domain & IP information
IP Address | AS Autonomous System | ||
---|---|---|---|
1 49 | 173.199.178.36 173.199.178.36 | 32244 (LIQUIDWEB) (LIQUIDWEB) | |
3 | 2a00:1450:400... 2a00:1450:4001:82b::2008 | 15169 (GOOGLE) (GOOGLE) | |
2 | 2a00:1450:400... 2a00:1450:4001:82b::200a | 15169 (GOOGLE) (GOOGLE) | |
4 | 2a00:1450:400... 2a00:1450:4001:827::200e | 15169 (GOOGLE) (GOOGLE) | |
4 | 2a00:1450:400... 2a00:1450:4001:810::2003 | 15169 (GOOGLE) (GOOGLE) | |
1 | 2a00:1450:400... 2a00:1450:400c:c07::9b | 15169 (GOOGLE) (GOOGLE) | |
10 | 2a00:1450:400... 2a00:1450:4001:831::200e | 15169 (GOOGLE) (GOOGLE) | |
1 2 | 2a00:1450:400... 2a00:1450:4001:827::2002 | 15169 (GOOGLE) (GOOGLE) | |
1 | 2a00:1450:400... 2a00:1450:4001:82a::2006 | 15169 (GOOGLE) (GOOGLE) | |
4 | 2a00:1450:400... 2a00:1450:4001:827::200a | 15169 (GOOGLE) (GOOGLE) | |
1 | 2a00:1450:400... 2a00:1450:4001:830::2004 | 15169 (GOOGLE) (GOOGLE) | |
1 | 2a00:1450:400... 2a00:1450:4001:828::2001 | 15169 (GOOGLE) (GOOGLE) | |
1 | 2a00:1450:400... 2a00:1450:4001:812::2016 | 15169 (GOOGLE) (GOOGLE) | |
2 | 2a00:1450:400... 2a00:1450:4001:82a::2003 | 15169 (GOOGLE) (GOOGLE) | |
83 | 15 |
ASN32244 (LIQUIDWEB, US)
PTR: host.ggcomm.net
www.lightstonevc.com |
ASN15169 (GOOGLE, US)
www.googletagmanager.com |
ASN15169 (GOOGLE, US)
www.google-analytics.com |
ASN15169 (GOOGLE, US)
googleads.g.doubleclick.net |
ASN15169 (GOOGLE, US)
static.doubleclick.net |
Apex Domain Subdomains |
Transfer | |
---|---|---|
49 |
lightstonevc.com
1 redirects
www.lightstonevc.com |
2 MB |
10 |
youtube.com
www.youtube.com — Cisco Umbrella Rank: 96 |
802 KB |
6 |
gstatic.com
fonts.gstatic.com www.gstatic.com |
95 KB |
6 |
googleapis.com
fonts.googleapis.com — Cisco Umbrella Rank: 44 jnn-pa.googleapis.com — Cisco Umbrella Rank: 276 |
32 KB |
4 |
doubleclick.net
1 redirects
stats.g.doubleclick.net — Cisco Umbrella Rank: 84 googleads.g.doubleclick.net — Cisco Umbrella Rank: 43 static.doubleclick.net — Cisco Umbrella Rank: 323 |
2 KB |
4 |
google-analytics.com
www.google-analytics.com — Cisco Umbrella Rank: 32 |
21 KB |
3 |
googletagmanager.com
www.googletagmanager.com — Cisco Umbrella Rank: 61 |
125 KB |
1 |
ytimg.com
i.ytimg.com — Cisco Umbrella Rank: 113 |
34 KB |
1 |
ggpht.com
yt3.ggpht.com — Cisco Umbrella Rank: 231 |
3 KB |
1 |
google.com
www.google.com — Cisco Umbrella Rank: 2 |
15 KB |
83 | 10 |
Domain | Requested by | |
---|---|---|
49 | www.lightstonevc.com |
1 redirects
www.lightstonevc.com
|
10 | www.youtube.com |
www.lightstonevc.com
www.youtube.com |
4 | jnn-pa.googleapis.com |
www.youtube.com
|
4 | fonts.gstatic.com |
fonts.googleapis.com
www.youtube.com |
4 | www.google-analytics.com |
www.googletagmanager.com
www.google-analytics.com |
3 | www.googletagmanager.com |
www.lightstonevc.com
www.googletagmanager.com |
2 | www.gstatic.com |
www.youtube.com
www.gstatic.com |
2 | googleads.g.doubleclick.net |
1 redirects
www.youtube.com
|
2 | fonts.googleapis.com |
www.lightstonevc.com
|
1 | i.ytimg.com |
www.youtube.com
|
1 | yt3.ggpht.com |
www.youtube.com
|
1 | www.google.com |
www.youtube.com
|
1 | static.doubleclick.net |
www.youtube.com
|
1 | stats.g.doubleclick.net |
www.google-analytics.com
|
83 | 14 |
This site contains links to these domains. Also see Links.
Subject Issuer | Validity | Valid | |
---|---|---|---|
lightstonevc.com R3 |
2022-09-20 - 2022-12-19 |
3 months | crt.sh |
*.google-analytics.com GTS CA 1C3 |
2022-09-12 - 2022-12-05 |
3 months | crt.sh |
upload.video.google.com GTS CA 1C3 |
2022-09-12 - 2022-12-05 |
3 months | crt.sh |
*.gstatic.com GTS CA 1C3 |
2022-09-12 - 2022-12-05 |
3 months | crt.sh |
*.g.doubleclick.net GTS CA 1C3 |
2022-09-12 - 2022-12-05 |
3 months | crt.sh |
*.google.com GTS CA 1C3 |
2022-09-12 - 2022-12-05 |
3 months | crt.sh |
*.doubleclick.net GTS CA 1C3 |
2022-09-12 - 2022-12-05 |
3 months | crt.sh |
www.google.com GTS CA 1C3 |
2022-09-12 - 2022-12-05 |
3 months | crt.sh |
*.googleusercontent.com GTS CA 1C3 |
2022-09-12 - 2022-12-05 |
3 months | crt.sh |
edgestatic.com GTS CA 1C3 |
2022-09-12 - 2022-12-05 |
3 months | crt.sh |
This page contains 2 frames:
Primary Page:
https://www.lightstonevc.com/
Frame ID: D6D8EE77D7C238774E8785D6F1507D32
Requests: 60 HTTP requests in this frame
Frame:
https://www.youtube.com/embed/ptFE03h7KfE?feature=oembed&wmode=opaque&wmode=opaque&rel=0
Frame ID: 95E0E49832D650DE9C607485DEE0A2DD
Requests: 22 HTTP requests in this frame
Screenshot
Page Title
Lightstone VenturesPage URL History Show full URLs
-
http://www.lightstonevc.com/
HTTP 301
https://www.lightstonevc.com/ Page URL
Detected technologies
WordPress (CMS) ExpandDetected patterns
- <link rel=["']stylesheet["'] [^>]+/wp-(?:content|includes)/
- /wp-(?:content|includes)/
Google Analytics (Analytics) Expand
Detected patterns
- google-analytics\.com/(?:ga|urchin|analytics)\.js
Google Font API (Font Scripts) Expand
Detected patterns
- <link[^>]* href=[^>]+fonts\.(?:googleapis|google)\.com
Google Tag Manager (Tag Managers) Expand
Detected patterns
- googletagmanager\.com/gtag/js
Slick (JavaScript Libraries) Expand
Detected patterns
- (?:/([\d.]+))?/slick(?:\.min)?\.js
jQuery (JavaScript Libraries) Expand
Detected patterns
- jquery.*\.js(?:\?ver(?:sion)?=([\d.]+))?
jQuery Migrate (JavaScript Libraries) Expand
Detected patterns
- jquery[.-]migrate(?:-([\d.]+))?(?:\.min)?\.js(?:\?ver=([\d.]+))?
Page Statistics
413 Outgoing links
These are links going to different origins than the main page.
Title: Login
Search URL Search Domain Scan URL
Title: acceleronpharma.com
Search URL Search Domain Scan URL
Title: Acceleron Announces ACE-083 Phase 1 Results at the 14th International Congress on Neuromuscular Diseases
Search URL Search Domain Scan URL
Title: Acceleron was named 'Exit of the Year' and Acceleron's John Knopf was named 'Entrepreneur of the Year - Healthcare.' at 2014 NEVY Awards
Search URL Search Domain Scan URL
Title: Acceleron, Celgene and Collaborators Announce Two Publications in Nature Medicine Describing Sotatercept and ACE-536 Therapeutic Potential in Beta-thalassemia and Myelodysplastic Syndromes
Search URL Search Domain Scan URL
Title: alchemab.com
Search URL Search Domain Scan URL
Title: Alchemab Therapeutics Appoints Young T. Kwon, PhD as Chief Financial and Operating Officer
Search URL Search Domain Scan URL
Title: Alchemab's new well-connected CEO will lead biotech on journey to address hard-to-treat diseases
Search URL Search Domain Scan URL
Title: AstraZeneca taps antibody-mining startup Alchemab to dig into prostate cancer
Search URL Search Domain Scan URL
Title: Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics
Search URL Search Domain Scan URL
Title: allaytx.com
Search URL Search Domain Scan URL
Title: A non-opioid pain startup believes it can top the bupivacaine market — and it's thinking in terms of weeks, not days
Search URL Search Domain Scan URL
Title: alxoncology.com
Search URL Search Domain Scan URL
Title: ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma
Search URL Search Domain Scan URL
Title: ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics
Search URL Search Domain Scan URL
Title: ALX Oncology Announces Pricing of Upsized Public Offering of Common Stock
Search URL Search Domain Scan URL
Title: Immuno-oncology biotech ALX Oncology prices upsized IPO at $19, above the range
Search URL Search Domain Scan URL
Title: After $105M funding round, ALX Oncology nabs FDA fast-track tag for cancer hopeful
Search URL Search Domain Scan URL
Title: ALX Oncology Announces Closing of $105 Million Series C Financing
Search URL Search Domain Scan URL
Title: ALX Oncology Presents New Data from Fully Enrolled ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors
Search URL Search Domain Scan URL
Title: ALX Oncology Presents Updated Data from ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors
Search URL Search Domain Scan URL
Title: Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical Trial in Patients with Advanced Solid Tumors and Lymphoma
Search URL Search Domain Scan URL
Title: ALX Oncology Presents Initial Data from the ALX148 Clinical Trial Non-Hodgkin Lymphoma Combination Cohort at the 61st American Society of Hematology (ASH)
Search URL Search Domain Scan URL
Title: Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical Trial in Patients with Advanced Solid Tumors and Lymphoma
Search URL Search Domain Scan URL
Title: Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma
Search URL Search Domain Scan URL
Title: BioCentury Emerging Company Profile of Alexo Therapeutics
Search URL Search Domain Scan URL
Title: thefoundry.com
Search URL Search Domain Scan URL
Title: ardian.com
Search URL Search Domain Scan URL
Title: atsenatx.com
Search URL Search Domain Scan URL
Title: Eyeing phase 3, Atsena raises $55M financing for blindness gene therapy
Search URL Search Domain Scan URL
Title: amgen.com
Search URL Search Domain Scan URL
Title: calahealth.com
Search URL Search Domain Scan URL
Title: Cala Health’s real-world study validates its wearable’s long-term efficacy
Search URL Search Domain Scan URL
Title: Cala Health Tackles Hand Tremors With Bioelectronic Treatment
Search URL Search Domain Scan URL
Title: SK Biopharmaceuticals partners with Cala to fuel innovation in neurology
Search URL Search Domain Scan URL
Title: New Research Presented at AAN Demonstrates Burden Associated with Essential Tremor and the Unmet Patient Need
Search URL Search Domain Scan URL
Title: Cala Health announces new chief commercial, financial officers amid leadership expansion
Search URL Search Domain Scan URL
Title: Cala Health Is Building Momentum By Expanding Affordable Access for Patients with Essential Tremor
Search URL Search Domain Scan URL
Title: The Top 25 Women Leaders in Medical Devices of 2022
Search URL Search Domain Scan URL
Title: Cala Health Raises $77M to Expand Patient Access and Fuel Continued Innovation
Search URL Search Domain Scan URL
Title: Cala Health wearables shown to decrease tremor movement
Search URL Search Domain Scan URL
Title: The 18 most innovative medical devices of 2021
Search URL Search Domain Scan URL
Title: 52 Women-Led Startups Driving The Future Of HealthTech And FemTech
Search URL Search Domain Scan URL
Title: Med-Tech Innovation News spoke to Renee Ryan, CEO of Cala Health, about its work tackling chronic diseases.
Search URL Search Domain Scan URL
Title: Cala Health and University of California, San Francisco Announce Partnership to Develop Next-Generation, Smart Neuromodulation Therapies
Search URL Search Domain Scan URL
Title: The Top 25 Women Leaders in Consumer HealthTech of 2021
Search URL Search Domain Scan URL
Title: Why Medtech Founders Should Not Over-Focus on Dilution: Interview with Renee Ryan, CEO of Cala Health
Search URL Search Domain Scan URL
Title: Cala Health Announces Expansion of Executive Team with Steve Higa and Greg Schulte
Search URL Search Domain Scan URL
Title: Cala Health Reports New Data Presented at ISPOR, Highlighting Essential Tremor (ET)-Related Comorbidities and Economic Burden
Search URL Search Domain Scan URL
Title: Patients With Essential Tremor Experience High Economic Burden
Search URL Search Domain Scan URL
Title: The Ultimate List of Private Medtech Companies to Watch (Updated)
Search URL Search Domain Scan URL
Title: 7 Companies Developing Bioelectronic Devices
Search URL Search Domain Scan URL
Title: The Top 25 Women Leaders in Medical Devices of 2021
Search URL Search Domain Scan URL
Title: Cala Health Receives FDA Breakthrough Device Designation for Cala Trio™ Therapy to Treat Action Tremors in Parkinson's Disease Read more: http://www.digitaljournal.com/pr/4850531#ixzz6bdadGbzb
Search URL Search Domain Scan URL
Title: Cala Health’s wrist-worn stimulator improves tremor control in real-world study
Search URL Search Domain Scan URL
Title: The Galien Foundation Introduces 2020 Prix Galien USA Nominees in "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" Categories
Search URL Search Domain Scan URL
Title: Cala Health aims to restore functionality to essential tremor patients with wearables
Search URL Search Domain Scan URL
Title: THIS WEARABLE CAN STIMULATE NERVES TO EFFECTIVELY CANCEL OUT HAND-TREMORS… AND IT’S A WATCH TOO.
Search URL Search Domain Scan URL
Title: Cala Health Applauded by Frost & Sullivan for Revolutionizing the Essential Tremor Market with its Body-worn Neuromodulation Therapy, Cala Trio™
Search URL Search Domain Scan URL
Title: Cala Health Names Veteran Leader Renee Ryan as Chief Executive Officer
Search URL Search Domain Scan URL
Title: Cala Health raises $50M ahead of commercial launch of its bioelectric stimulation device
Search URL Search Domain Scan URL
Title: Stealth Stanford spinout Cala Health raises $18M for wearable device that treats hand and wrist tremors
Search URL Search Domain Scan URL
Title: calithera.com
Search URL Search Domain Scan URL
Title: Calithera Biosciences Awarded up to $2.4M from Cystic Fibrosis Foundation to Support Clinical Development of Arginase Inhibitor, CB-280
Search URL Search Domain Scan URL
Title: Calithera Biosciences Initiates Phase 1b Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis
Search URL Search Domain Scan URL
Title: Calithera Biosciences Completes Patient Enrollment in Randomized CANTATA Trial of Telaglenastat and Cabozantinib in Advanced Renal Cell Carcinoma
Search URL Search Domain Scan URL
Title: Calithera Biosciences Initiates Phase 1 Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis
Search URL Search Domain Scan URL
Title: Calithera Biosciences Announces FDA Acceptance of Investigational New Drug Application for CB-1158, a Novel Arginase Inhibitor Targeting an Immune Metabolic Checkpoint
Search URL Search Domain Scan URL
Title: Is Calithera the next biotech IPO hopeful?
Search URL Search Domain Scan URL
Title: cardiacbooster.com
Search URL Search Domain Scan URL
Title: carricktherapeutics.com
Search URL Search Domain Scan URL
Title: Carrick Therapeutics Announces Collaboration with Roche to Evaluate Novel Samuraciclib Combination to Treat HR+ Breast Cancer
Search URL Search Domain Scan URL
Title: Carrick Therapeutics Announces Plan to Establish US Operations and Appointment of Tim Pearson as CEO
Search URL Search Domain Scan URL
Title: Carrick Therapeutics In-Licenses Targeted Ovarian Cancer Treatment From BTG and Appoints George Golumbeski as Chairman
Search URL Search Domain Scan URL
Title: New Startup Carrick Therapeutics Launches With $95 Million and Taps Former AstraZeneca PLC-Eli Lilly Exec as CEO
Search URL Search Domain Scan URL
Title: catabasis.com
Search URL Search Domain Scan URL
Title: Catabasis Pharmaceuticals Names Ben Harshbarger Senior Vice President, General Counsel
Search URL Search Domain Scan URL
Title: Catabasis Pharmaceuticals Announces Phase 3 PolarisDMD Trial Enrolled Expected Patient Population
Search URL Search Domain Scan URL
Title: Catabasis Pharmaceuticals Announces The Phase 3 PolarisDMD Trial Of Edasalonexent In Duchenne Muscular Dystrophy Has Exceeded Target Enrollment
Search URL Search Domain Scan URL
Title: Catabasis Pharmaceuticals Announces Publication Of Phase 1 Clinical Results Of Edasalonexent (CAT-1004) In Duchenne Muscular Dystrophy
Search URL Search Domain Scan URL
Title: Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne Muscular Dystrophy
Search URL Search Domain Scan URL
Title: Catabasis Pharmaceuticals Reports Positive Results From Open-Label Extension Of Phase 2 MoveDMD® Trial Evaluating Edasalonexent In Duchenne Muscular Dystrophy And Plans To Initiate Phase 3 Clinical Trial In First Half 2018
Search URL Search Domain Scan URL
Title: Crossing paths LINKING INFLAMMATION AND OXIDATION IN ALS
Search URL Search Domain Scan URL
Title: Catabasis Pharmaceuticals Announces Pricing Of Initial Public Offering
Search URL Search Domain Scan URL
Title: Catamaran Bio Presents Preclinical Data Supporting Novel Engineered CAR-NK Cell Therapies For Treating Solid Tumors
Search URL Search Domain Scan URL
Title: Catamaran Bio Appoints Cherry Thomas, MD, as Chief Medical Officer
Search URL Search Domain Scan URL
Title: Catamaran Bio Appoints Frank Lee as Chair of Its Board of Directors
Search URL Search Domain Scan URL
Title: Catamaran Bio Expands Collaboration for CAR‑NK Cell Engineering with the University of Minnesota and Secures an Exclusive Patent License to Next Generation Manufacturing Technologies
Search URL Search Domain Scan URL
Title: Catamaran Bio Announces Appointment of Michael DeRidder, PhD, as Senior Vice President, Corporate Strategy and New Product Planning
Search URL Search Domain Scan URL
Title: Catamaran Bio Presents Preclinical Data Supporting CAT-248, an Off-the-Shelf CD70-Targeted CAR-NK Cell Therapy for the Treatment of CD70-Expressing Cancers
Search URL Search Domain Scan URL
Title: Catamaran Bio Announces Lead CAR-NK Cell Therapy Programs and Upcoming Data Presentation at ASH 2021
Search URL Search Domain Scan URL
Title: Catamaran Bio Announces Appointment of Joseph Gold, PhD, as Vice President, Technical Operations and Manufacturing
Search URL Search Domain Scan URL
Title: Catamaran Bio and Bio-Techne Announce Expanded Collaboration for CAR‑NK Cell Manufacturing Technologies
Search URL Search Domain Scan URL
Title: Catamaran Bio Announces Appointment of Scott Holmes as Chief Financial Officer
Search URL Search Domain Scan URL
Title: Catamaran Bio Announces Appointment of Dr. Alvin Shih as President and Chief Executive Officer
Search URL Search Domain Scan URL
Title: Catamaran Bio sails into the CAR-NK waters with a $42M launch round
Search URL Search Domain Scan URL
Title: Catamaran Bio Launches with $42 Million Financing to Develop Off‑the‑Shelf CAR-NK Cell Therapies to Treat Solid Tumors
Search URL Search Domain Scan URL
Title: cerevance.com
Search URL Search Domain Scan URL
Title: Merck is back in Alzheimer's saddle with $1B+ Cerevance pact, years after dropping the BACE
Search URL Search Domain Scan URL
Title: Cerevance’s CVN058 Achieves Primary Endpoint in Phase Ib Schizophrenia Cognition Study
Search URL Search Domain Scan URL
Title: Gates, GV chip into $45M round for CNS biotech Cerevance
Search URL Search Domain Scan URL
Title: Takeda and Cerevance Team Up to Take on GI Diseases
Search URL Search Domain Scan URL
Title: Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424
Search URL Search Domain Scan URL
Title: Industry Central Nervous System Specialist Lee Dawson, Ph.D. Joins Cerevance as VP of Neuroscience
Search URL Search Domain Scan URL
Title: Cerevance Announces First-in-Human Dosing of CVN424 for the Treatment of Parkinson’s Disease
Search URL Search Domain Scan URL
Title: Takeda and Lightstone join forces to fund and launch neuroscience upstart
Search URL Search Domain Scan URL
Title: claretmedical.com
Search URL Search Domain Scan URL
Title: Boston Scientific Announces Agreement to Acquire Claret Medical, Inc.
Search URL Search Domain Scan URL
Title: Claret Medical Receives FDA Clearance to Market Sentinel Cerebral Protection System in the U.S.
Search URL Search Domain Scan URL
Title: FDA Advisory Committee Strongly Supports Granting De Novo Application For The First Cerebral Protection System For Transcatheter Aortic Valve Replacement (TAVR)
Search URL Search Domain Scan URL
Title: Results from U.S. Pivotal IDE Trial Show That Sentinel Cerebral Protection System Protects Patients During Transcatheter Aortic Valve Replacement
Search URL Search Domain Scan URL
Title: CLARET MEDICAL SUBMITS MARKETING APPLICATION TO FDA FOR US CLEARANCE OF FIRST CEREBRAL PROTECTION SYSTEM FOR TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR)
Search URL Search Domain Scan URL
Title: CLARET MEDICAL ANNOUNCES SENTINEL PIVOTAL IDE TRIAL TO BE FEATURED IN LATE-BREAKING TRIAL SESSION AT TRANSCATHETER CARDIOVASCULAR THERAPEUTICS (TCT) CONFERENCE
Search URL Search Domain Scan URL
Title: Endovascular Filter Device Helps Prevent Periprocedural Stroke
Search URL Search Domain Scan URL
Title: Claret Medical Release: New Study Shows Definitive Neurocognitive Benefit For Patients Protected By Sentinel Cerebral Protection System During Transcatheter Aortic Valve Replacement (TAVR)
Search URL Search Domain Scan URL
Title: contegomedical.com
Search URL Search Domain Scan URL
Title: Raleigh medical device company Contego Medical raises more than $15M
Search URL Search Domain Scan URL
Title: Contego Medical Receives CE Mark Approval for Next Generation Carotid Stent
Search URL Search Domain Scan URL
Title: Contego Medical Announces the Start of Enrollment in the PERFORMANCE II Carotid Stenting Clinical Trial
Search URL Search Domain Scan URL
Title: cyteir.com
Search URL Search Domain Scan URL
Title: CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies
Search URL Search Domain Scan URL
Title: Cyteir Therapeutics Announces First Patient Dosed in Phase 2 with CYT-0851
Search URL Search Domain Scan URL
Title: Cyteir Therapeutics Announces the Appointment of John F. Thero to Board of Directors
Search URL Search Domain Scan URL
Title: Cyteir Therapeutics Announces First Patient Dosed in Phase 1 Combination Trial With CYT-0851
Search URL Search Domain Scan URL
Title: Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to Board of Directors
Search URL Search Domain Scan URL
Title: Cyteir Therapeutics Selected to Join Russell 2000® Index
Search URL Search Domain Scan URL
Title: Cyteir Therapeutics Announces Pricing of Initial Public Offering
Search URL Search Domain Scan URL
Title: Cyteir Therapeutics Aims For $126 Million IPO
Search URL Search Domain Scan URL
Title: Cyteir Therapeutics Announces Presentation of First-in-Human Phase 1/2 Study of CYT-0851
Search URL Search Domain Scan URL
Title: Oncology biotech Cyteir Therapeutics files for a $100 million IPO
Search URL Search Domain Scan URL
Title: Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials of Lead RAD51 Program
Search URL Search Domain Scan URL
Title: Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer and Expands Senior Leadership Team
Search URL Search Domain Scan URL
Title: Cyteir Therapeutics Secures Additional $40.2 Million in Its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor
Search URL Search Domain Scan URL
Title: Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors
Search URL Search Domain Scan URL
Title: Bound for the clinic with a new approach to synthetic lethality, Cyteir bags $29M
Search URL Search Domain Scan URL
Title: Cyteir Bags $29M to Tap “Self Destruct” in Cancers, Immune Diseases
Search URL Search Domain Scan URL
Title: lilly.com/discovery/research-and-scientific-discovery/disarm-therapeutics
Search URL Search Domain Scan URL
Title: Lilly Announces Agreement to Acquire Disarm Therapeutics
Search URL Search Domain Scan URL
Title: Disarm Therapeutics Appoints Veteran Biotech Executive Scott Holmes as Chief Financial Officer
Search URL Search Domain Scan URL
Title: Disarm Therapeutics Reports Preclinical Data Demonstrating Small Molecule SARM1 Inhibitors Preserve Both Axonal Structure and Function In Vitro and In Vivo
Search URL Search Domain Scan URL
Title: Disarm Therapeutics Presents New Data Validating Role of SARM1 in Axonal Degeneration
Search URL Search Domain Scan URL
Title: earlens.com
Search URL Search Domain Scan URL
Title: Earlens Shares FDA Historical Ruling on OTC Hearing Aids
Search URL Search Domain Scan URL
Title: New device aims to provide better sound than hearing aids
Search URL Search Domain Scan URL
Title: Earlens Wins "Best CEO" Award
Search URL Search Domain Scan URL
Title: New device for hearing loss acts like a contact lens for the ear
Search URL Search Domain Scan URL
Title: Earlens wins "Best Leadership Team" and "Best CEOs for Diversity" awards
Search URL Search Domain Scan URL
Title: Study demonstrates significant listening advantages with Earlens hearing technology
Search URL Search Domain Scan URL
Title: Earlens Wins Gold 2020 Edison Award for its Revolutionary Earlens® Contact Hearing Solution
Search URL Search Domain Scan URL
Title: Earlens inks new partnership with Verily
Search URL Search Domain Scan URL
Title: Tackling the Burden and Shame of Hearing Loss
Search URL Search Domain Scan URL
Title: Comparison of Real-world Bandwidth in Hearing Aids vs Earlens Light-driven Hearing Aid System
Search URL Search Domain Scan URL
Title: Earlens Selects iBASEt to Support 3D Printing of Revolutionary Hearing Aid
Search URL Search Domain Scan URL
Title: Earlens raises $51M to launch laser-based hearing aid after FDA nod
Search URL Search Domain Scan URL
Title: EarLens hearing aid uses laser light to transmit sound
Search URL Search Domain Scan URL
Title: FDA Permits Marketing Of New Laser-Based Hearing Aid With Potential For Broad Sound Amplification
Search URL Search Domain Scan URL
Title: endogastricsolutions.com
Search URL Search Domain Scan URL
Title: EndoGastric® Solutions Announces Further Expansion of Medicare Reimbursement for Transoral Incisionless Fundoplication (TIF®) 2.0 Procedure
Search URL Search Domain Scan URL
Title: Durable Treatment Of GERD With TIF 2.0: A Surgical Products Q&A
Search URL Search Domain Scan URL
Title: EndoGastric Solutions Announces Publication of Long-Term Data Demonstrating TIF® 2.0 Procedure Offers Durable Treatment of Chronic GERD
Search URL Search Domain Scan URL
Title: Device treats severe heartburn at the source
Search URL Search Domain Scan URL
Title: EndoGastric Solutions touts U.S. reimbursement win
Search URL Search Domain Scan URL
Title: FDA Clears Next-Generation Version of EndoGastric Solutions’ EsophyX® Device
Search URL Search Domain Scan URL
Title: EndoGastric Solutions gets $50M for “natural orifice” device to treat GERD
Search URL Search Domain Scan URL
Title: EndoGastric Solutions Announces New Sham-Controlled European Study Demonstrates Transoral Incisionless Fundoplication (TIF) Procedure as Effective Alternative for Daily PPI Treatment
Search URL Search Domain Scan URL
Title: EndoGastric Solutions Announces AMA Assignment of CPT Code and Short Form Descriptor
Search URL Search Domain Scan URL
Title: EndoGastric skips toward positive study review for GERD device
Search URL Search Domain Scan URL
Title: GERD Device Maker Uses Clinical Data to Prove Its Point
Search URL Search Domain Scan URL
Title: GERD transoral surgical startup releases sham-controlled data as it awaits reimbursement code
Search URL Search Domain Scan URL
Title: EndoGastric Solutions Announces Publication of Landmark Data in Gastroenterology Demonstrating Superiority of Transoral Incisionless Fundoplication For Treatment of Troublesome Regurgitation
Search URL Search Domain Scan URL
Title: EndoGastric Solutions Names Industry Veteran Skip Baldino CEO
Search URL Search Domain Scan URL
Title: fire1foundry.com
Search URL Search Domain Scan URL
Title: FIRE1 raises $50M to develop remote heart monitoring device
Search URL Search Domain Scan URL
Title: Exits and IPOs the best medicine for Ireland’s medtech hub (video)
Search URL Search Domain Scan URL
Title: Medtronic backs stealthy Foundry startup as it nabs $7.5M for novel remote patient monitoring
Search URL Search Domain Scan URL
Title: fiveprime.com
Search URL Search Domain Scan URL
Title: Five Prime, Bristol Shake Hands Again in New $350M Cancer Pact
Search URL Search Domain Scan URL
Title: Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration Agreement to Discover Novel Immuno-Oncology Therapies for Two Immune Checkpoint Pathways
Search URL Search Domain Scan URL
Title: flex-pharma.com
Search URL Search Domain Scan URL
Title: Panelists Select 19 Companies for the 2016 Small-Cap Biotech Watchlist
Search URL Search Domain Scan URL
Title: Flex Pharma Announces Pricing Of Initial Public Offering
Search URL Search Domain Scan URL
Title: geminitherapeutics.com
Search URL Search Domain Scan URL
Title: Gemini Therapeutics and Disc Medicine Announce Merger Agreement
Search URL Search Domain Scan URL
Title: Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at Clinical Trials at the Summit
Search URL Search Domain Scan URL
Title: Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of Board of Directors
Search URL Search Domain Scan URL
Title: Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer
Search URL Search Domain Scan URL
Title: Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry Age-Related Macular Degeneration (AMD) in Patients with High-Risk Genetic Variants
Search URL Search Domain Scan URL
Title: Gemini Therapeutics Appoints Brian Piekos as Chief Financial Officer
Search URL Search Domain Scan URL
Title: Gemini Therapeutics Debuts as Publicly Traded Precision Medicine Company Focused on Age-Related Macular Degeneration
Search URL Search Domain Scan URL
Title: Gemini Therapeutics Announces Initiation of GEM103 Phase 2a Study as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy
Search URL Search Domain Scan URL
Title: Gemini Therapeutics Announces FDA Fast Track Designation Granted for GEM103 for the Treatment of Dry Age-Related Macular Degeneration (AMD) in Patients With Complement Factor H (CFH) Loss of Function Gene Variants
Search URL Search Domain Scan URL
Title: Gemini Therapeutics and FS Development Corp. Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused on Age-Related Macular Degeneration
Search URL Search Domain Scan URL
Title: Foresite pulls Gemini Therapeutics to Nasdaq in a quick $216M SPAC flip
Search URL Search Domain Scan URL
Title: Gemini Therapeutics Appoints Marc E. Uknis, MD, FACS as Chief Medical Officer
Search URL Search Domain Scan URL
Title: Gemini Therapeutics Appoints David Lubner as Independent Director
Search URL Search Domain Scan URL
Title: Gemini Therapeutics and Singapore Eye Research Institute Enter Into Research Collaboration to Explore New Targets for Age-related Macular Degeneration
Search URL Search Domain Scan URL
Title: Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry Age-related Macular Degeneration
Search URL Search Domain Scan URL
Title: Gemini Therapeutics Announces Leadership Appointment
Search URL Search Domain Scan URL
Title: Gemini Therapeutics Announces the Initiation of CLARITY, a Disease Registry and Natural History Study of Subjects with Dry AMD and High-Risk Genotypes
Search URL Search Domain Scan URL
Title: Armed with $42.5M, Gemini embraces the Goldilocks strategy in bringing precision med to AMD
Search URL Search Domain Scan URL
Title: gidynamics.com
Search URL Search Domain Scan URL
Title: GI Dynamics Announces the Appointment of Medical Device Industry Veteran Scott Schorer as President & Chief Executive Officer
Search URL Search Domain Scan URL
Title: gynesonics.com/us
Search URL Search Domain Scan URL
Title: Gynesonics Announces Positive Coverage Policy Decision Published by Cigna for Treatment of Uterine Fibroids with the Sonata System
Search URL Search Domain Scan URL
Title: New Guidance from the American College of Obstetricians and Gynecologists for Fibroid Management Supports Incisionless Transcervical Radiofrequency Ablation as a Uterus-Preserving Treatment Option
Search URL Search Domain Scan URL
Title: Gynesonics Announces Publication of SAGE Global Registry Preliminary Results: Real-World Usage Corroborates the Safety and Applicability of Sonata Transcervical Fibroid Ablation
Search URL Search Domain Scan URL
Title: Gynesonics Announces Publication of Clinical Study Analysis Demonstrating Effectiveness of the Sonata System in Treating Submucous and Large Symptomatic Uterine Fibroids
Search URL Search Domain Scan URL
Title: Gynesonics Appoints Susan Stimson to Its Board of Directors
Search URL Search Domain Scan URL
Title: Gynesonics Announces Centers for Medicare and Medicaid Services Final Rule Approves Ambulatory Surgery Centers as a Site of Service for Transcervical Uterine Fibroid Ablation with Device Intensive Designation
Search URL Search Domain Scan URL
Title: Gynesonics Announces That Detroit Medical Center Huron Valley-Sinai Hospital has Introduced Sonata, A New Innovative, Incision-Free Treatment for Symptomatic Uterine Fibroids
Search URL Search Domain Scan URL
Title: Runway Growth Capital Announces a Senior Secured Term Loan of $50 Million to Gynesonics
Search URL Search Domain Scan URL
Title: Gynesonics gets $43M to back pivotal trial of uterine fibroid ablation device
Search URL Search Domain Scan URL
Title: Gynesonics Names Christopher M. Owens President, Chief Executive Officer
Search URL Search Domain Scan URL
Title: ligaturetx.com
Search URL Search Domain Scan URL
Title: Ligature Therapeutics Launches, Raises USD $6M in Seed Financing
Search URL Search Domain Scan URL
Title: EXPERIMENTAL DRUG DEVELOPMENT CENTRE LAUNCHES SPIN-OFF TO DEVELOP TARGETED PROTEIN DEGRADERS FOR TREATING INTRACTABLE DISEASES
Search URL Search Domain Scan URL
Title: locanabio.com
Search URL Search Domain Scan URL
Title: Gene Therapy Lowers Toxic RNA Due to C9ORF72 Mutations in ALS
Search URL Search Domain Scan URL
Title: Locanabio Expands Leadership Team with Appointment of Kat Lange as Chief Financial Officer
Search URL Search Domain Scan URL
Title: Locanabio Expands Leadership Team with Appointment of Chief Scientific Officer and Chief Medical Officer
Search URL Search Domain Scan URL
Title: Locanabio Announces Upcoming Preclinical Data Presentations at American Society of Gene and Cell Therapy Annual Meeting
Search URL Search Domain Scan URL
Title: Locanabio Announces $100 Million Series B Financing to Advance Portfolio of Novel RNA-Targeted Gene Therapies for Neurodegenerative, Neuromuscular and Retinal Diseases
Search URL Search Domain Scan URL
Title: Locana Expands Leadership Team with Appointment of Micah Mackison, as Chief Business Officer
Search URL Search Domain Scan URL
Title: Locana Expands Leadership Team with Appointment of former Casebia CEO, James Burns, Ph.D., as Chief Executive Officer
Search URL Search Domain Scan URL
Title: Locana, Fueled With $55M, Looks to Develop Fixes for Faulty RNA
Search URL Search Domain Scan URL
Title: MDA Awards Venture Philanthropy Grant to Locana to Develop Novel Treatment for Muscular Dystrophy
Search URL Search Domain Scan URL
Title: Arming Bodies with CRISPR to Fight Huntington’s Disease and ALS
Search URL Search Domain Scan URL
Title: medisixtx.com
Search URL Search Domain Scan URL
Title: MediSix Therapeutics Launches with USD$20M Series A Financing
Search URL Search Domain Scan URL
Title: MediSix Therapeutics Signs Exclusive Licensing Agreement with the National University of Singapore
Search URL Search Domain Scan URL
Title: microvention.com
Search URL Search Domain Scan URL
Title: mosaicbio.com
Search URL Search Domain Scan URL
Title: moximed.com
Search URL Search Domain Scan URL
Title: Moximed Closes Oversubscribed $50MM Financing Round
Search URL Search Domain Scan URL
Title: Moximed closes $50m Series C
Search URL Search Domain Scan URL
Title: Moximed’s AtlasTM Knee System Improves Pain Scores and Returns Function to Pre-Arthroplasty Patients with Medial Knee Osteoarthritis
Search URL Search Domain Scan URL
Title: CE Mark in hand, Moximed hatches U.S. approval strategy for knee stabilization implant
Search URL Search Domain Scan URL
Title: Moximed Announces CE Mark and First Commercial Use of AtlasTM Knee System
Search URL Search Domain Scan URL
Title: Moximed Closes $33MM Financing Round
Search URL Search Domain Scan URL
Title: nimbustx.com
Search URL Search Domain Scan URL
Title: Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Small Molecule Activators of AMPK
Search URL Search Domain Scan URL
Title: Nimbus Therapeutics Announces Expansion of Oral Allosteric TYK2 Inhibitor Program and Provides Additional Business Updates
Search URL Search Domain Scan URL
Title: Nimbus Therapeutics Announces $105 Million Private Financing to Advance Pipeline Including Multiple Clinical Programs
Search URL Search Domain Scan URL
Title: Nimbus Therapeutics Announces $60 Million Private Financing From New Investors to Advance Expanded Pipeline
Search URL Search Domain Scan URL
Title: Nimbus Therapeutics Presents Data on Novel HPK1 Inhibitor, Demonstrating Robust Inhibition of Tumor Growth In Vivo
Search URL Search Domain Scan URL
Title: Nimbus Therapeutics Announces Expansion of its Drug Discovery Pipeline Across Oncology, Immunology and Metabolism
Search URL Search Domain Scan URL
Title: Nimbus CEO Keiper: 'We're not just a one-hit wonder'
Search URL Search Domain Scan URL
Title: Nimbus Therapeutics Announces Identification of a Potent, Selective HPK1 Inhibitor With Robust In Vivo Activity
Search URL Search Domain Scan URL
Title: Nimbus Therapeutics Appoints Chief Medical Officer Annie C. Chen, M.D., MPH, to President of the Company’s Tyk2 Subsidiary
Search URL Search Domain Scan URL
Title: Celgene pens pact to join Bristol-Myers, Pfizer in R&D race
Search URL Search Domain Scan URL
Title: Gilead says first data on Nimbus NASH candidate are positive
Search URL Search Domain Scan URL
Title: Nimbus in full-on drug development partnership with Charles River
Search URL Search Domain Scan URL
Title: Fast biotech: Gilead hands $200M to computational wiz Nimbus as it speeds into PhII NASH trial
Search URL Search Domain Scan URL
Title: Nimbus Therapeutics Announces $200 Million Milestone Payment from Gilead Sciences for Allosteric ACC Inhibitor Program in Non-alcoholic Steatohepatitis (NASH)
Search URL Search Domain Scan URL
Title: Nimbus Therapeutics Announces Global License Agreement with Genentech
Search URL Search Domain Scan URL
Title: Pfizer joins a powerhouse syndicate backing $43M round for Nimbus
Search URL Search Domain Scan URL
Title: nuvaira.com
Search URL Search Domain Scan URL
Title: Targeted Lung Denervation Found Effective, Safe Over 3 Years of Follow-up
Search URL Search Domain Scan URL
Title: Nuvaira Announces FDA Breakthrough Designation for AIRFLOW-3 Pivotal Trial Device
Search URL Search Domain Scan URL
Title: Nuvaira Announces Chief Financial Officer and Pivotal Study Milestone
Search URL Search Domain Scan URL
Title: Nuvaira Announces a $79 Million Financing Round to Pursue Groundbreaking Treatment of COPD
Search URL Search Domain Scan URL
Title: Holaira Hosts Educational Symposium on Targeted Lung Denervation (TLD) in Obstructive Lung Disease at ERS
Search URL Search Domain Scan URL
Title: First COPD Patient Treated in Holaira's Sham Controlled Trial of Targeted Lung Denervation
Search URL Search Domain Scan URL
Title: Holaira Announces First Patient Treatment in Randomized Study of Targeted Lung Denervation for COPD
Search URL Search Domain Scan URL
Title: Plymouth-based Holaira raises $42 million
Search URL Search Domain Scan URL
Title: nalpropion.com
Search URL Search Domain Scan URL
Title: plexxikon.com
Search URL Search Domain Scan URL
Title: portola.com
Search URL Search Domain Scan URL
Title: powervisionlens.com
Search URL Search Domain Scan URL
Title: Alcon Announces Acquisition of PowerVision, Inc.
Search URL Search Domain Scan URL
Title: Alcon Acquires PowerVision for $285 Million
Search URL Search Domain Scan URL
Title: PowerVision - FierceMedicalDevices' 2016 Fierce 15
Search URL Search Domain Scan URL
Title: Barry Cheskin, CEO, president and co-founder of PowerVision, provides details on his company’s new partnership with Alcon.
Search URL Search Domain Scan URL
Title: Novartis' Alcon Partners With Eye Device Startup PowerVision
Search URL Search Domain Scan URL
Title: ACCOMMODATIVE IOL PROVIDES GOOD VISUAL ACUITY
Search URL Search Domain Scan URL
Title: A Fluid-Based Accommodating IOL
Search URL Search Domain Scan URL
Title: principiabio.com
Search URL Search Domain Scan URL
Title: promedior.com
Search URL Search Domain Scan URL
Title: Promedior Presents Positive Phase 2 Data for PRM-151 in Myelofibrosis at ASH Annual Meeting
Search URL Search Domain Scan URL
Title: Bristol-Myers forges $1.25B deal to beef up fibrosis pipeline in Promedior buyout
Search URL Search Domain Scan URL
Title: onyx.com
Search URL Search Domain Scan URL
Title: proverummedical.com
Search URL Search Domain Scan URL
Title: ProVerum: First Enrolment in the ProVIDE Clinical Study for BPH Treatment
Search URL Search Domain Scan URL
Title: rapharma.com
Search URL Search Domain Scan URL
Title: Ra Pharmaceuticals Supports 12th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases
Search URL Search Domain Scan URL
Title: Ra Pharmaceuticals Receives Orphan Drug Designation in the European Union for RA101495 for Treatment of Paroxysmal Nocturnal Hemoglobinuria
Search URL Search Domain Scan URL
Title: Ra Pharmaceuticals Announces Pricing of Initial Public Offering
Search URL Search Domain Scan URL
Title: Taking Aim at Alexion, Ra Pharma Heads to IPO Queue
Search URL Search Domain Scan URL
Title: Ra Pharmaceuticals Announces $58.5M Series B Financing
Search URL Search Domain Scan URL
Title: relievant.com
Search URL Search Domain Scan URL
Title: NBC News’ TODAY Features the Minimally Invasive Intracept® Procedure for Chronic Vertebrogenic Low Back Pain
Search URL Search Domain Scan URL
Title: Relievant Medsystems’ Intracept receives new CPT codes to aid reimbursement efforts
Search URL Search Domain Scan URL
Title: Relievant Medsystems Names Tyler Binney President and CEO
Search URL Search Domain Scan URL
Title: Relievant Medsystems Announces $70M Financing to Accelerate U.S. Commercialization of Intracept Procedure
Search URL Search Domain Scan URL
Title: Relievant Medsystems raises $36m
Search URL Search Domain Scan URL
Title: Relievant Medsystems wins FDA clearance for Intracept ablation device for low back pain
Search URL Search Domain Scan URL
Title: reprievecardio.com
Search URL Search Domain Scan URL
Title: Amicus Therapeutics to Acquire Rare Disease Company Scioderm, Inc.
Search URL Search Domain Scan URL
Title: secondgenome.com
Search URL Search Domain Scan URL
Title: Second Genome signs Gilead deal in IBD, biomarkers worth up to $1.5B-plus
Search URL Search Domain Scan URL
Title: Second Genome Partners with King's College London to Evaluate the Influence of the Microbiome in Landmark EAT Study
Search URL Search Domain Scan URL
Title: Monsanto Collaborates with Second Genome to use Microbiome Technology Platform to Accelerate Protein Discovery
Search URL Search Domain Scan URL
Title: Second Genome’s new CEO looks to neighboring Genentech as a model for pioneering a new field
Search URL Search Domain Scan URL
Title: Pfizer, Roche Embrace The Microbiome, Leading $43M Bet On Second Genome
Search URL Search Domain Scan URL
Title: Unraveling the Mysterious Function of the Microbiome
Search URL Search Domain Scan URL
Title: Medicine’s next frontier: The microbiome (Second Genome featured)
Search URL Search Domain Scan URL
Title: Evotec pairs up with Second Genome to gut out some R&D
Search URL Search Domain Scan URL
Title: Second Genome Advances Lead Microbiome Drug Development Program in Phase I Clinical Trial as a Treatment for Inflammatory Bowel Disease
Search URL Search Domain Scan URL
Title: What’s Lurking In Your Microbiome? Possibly, A Cure For Disease
Search URL Search Domain Scan URL
Title: Human microbiome: Boon or boondoggle for drugmakers?
Search URL Search Domain Scan URL
Title: Pfizer jumps on the microbiome bandwagon with expansive Second Genome deal
Search URL Search Domain Scan URL
Title: setpointmedical.com
Search URL Search Domain Scan URL
Title: SetPoint Medical enrols first patient in study of bioelectronic platform
Search URL Search Domain Scan URL
Title: SetPoint Medical Raises $64M in Preferred Stock Financing to Support Pivotal Trial for its Novel Bioelectronic Platform
Search URL Search Domain Scan URL
Title: SetPoint Medical Presents Positive Clinical Results in Crohn’s Disease
Search URL Search Domain Scan URL
Title: Breakthrough First-in-Human Study Shows Vagus Nerve Stimulation Significantly Reduces Rheumatoid Arthritis Symptoms, Inhibits Cytokine Production
Search URL Search Domain Scan URL
Title: shoulderinnovations.com
Search URL Search Domain Scan URL
Title: Shoulder Innovations Announces FDA Clearance of New InSet™ Stemless Humeral Implant
Search URL Search Domain Scan URL
Title: Reverse Shoulder Implant Reduces Glenoid Micro-Motion
Search URL Search Domain Scan URL
Title: Shoulder Innovations Relocates Corporate Headquarters
Search URL Search Domain Scan URL
Title: Shoulder Innovations Announces Exclusive License Agreement for Genesis Software Innovations PreView Shoulder™ Software
Search URL Search Domain Scan URL
Title: Shoulder Innovations Announces Equity Financing of $21.6M
Search URL Search Domain Scan URL
Title: spinewave.com
Search URL Search Domain Scan URL
Title: tallactherapeutics.com
Search URL Search Domain Scan URL
Title: Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors
Search URL Search Domain Scan URL
Title: Tallac Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for TAC-001, a First-in-Class Toll-like Receptor 9 (TLR9) Agonist Antibody Conjugate for Patients with Advanced Solid Tumors
Search URL Search Domain Scan URL
Title: Tallac Therapeutics Appoints Curtis Hecht as Chief Business Officer
Search URL Search Domain Scan URL
Title: Tallac Therapeutics Presents New Data on Toll-like Receptor Agonist Antibody Conjugate, TAC-001, at the 2021 Virtual Annual Meeting of the American Association for Cancer Research (AACR)
Search URL Search Domain Scan URL
Title: How a Peninsula startup with a fresh $62M round wants to get cancer to pay a toll
Search URL Search Domain Scan URL
Title: Tallac Therapeutics launches with $62M run by ALX Oncology vets, with an eye on next-gen cancer
Search URL Search Domain Scan URL
Title: tizonatx.com
Search URL Search Domain Scan URL
Title: Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300 Million
Search URL Search Domain Scan URL
Title: Gilead adds to string of cancer drug deals with Tizona stake
Search URL Search Domain Scan URL
Title: Tizona Initiates Clinical Development of TTX-080 in Advanced Cancers
Search URL Search Domain Scan URL
Title: AbbVie and Tizona Therapeutics Announce Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD39
Search URL Search Domain Scan URL
Title: Tizona signals full court press against regulatory T cells with $43M series B
Search URL Search Domain Scan URL
Title: With $70M in VC cash, Tizona takes a fresh approach to immuno-oncology
Search URL Search Domain Scan URL
Title: TIZONA THERAPEUTICS, INC., COMPLETES $43 MILLION SERIES B FINANCING
Search URL Search Domain Scan URL
Title: trotana.com
Search URL Search Domain Scan URL
Title: Medtronic to buy Twelve for $408M+, joining Abbott and Edwards on the transcatheter mitral valve bandwagon
Search URL Search Domain Scan URL
Title: vapotherm.com
Search URL Search Domain Scan URL
Title: verastem.com
Search URL Search Domain Scan URL
Title: vigilneuro.com
Search URL Search Domain Scan URL
Title: Vigil Neuroscience Announces $75 Million Private Placement Financing
Search URL Search Domain Scan URL
Title: Vigil Neuroscience Strengthens Board of Directors with Appointment of Suzanne Bruhn, Ph.D.
Search URL Search Domain Scan URL
Title: Vigil Neuroscience Expands VGL101 Phase 1 Trial to Australia
Search URL Search Domain Scan URL
Title: Vigil Neuroscience Expands Leadership Team and Board of Directors
Search URL Search Domain Scan URL
Title: Vigil Neuroscience Announces Pricing of Initial Public Offering
Search URL Search Domain Scan URL
Title: Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases
Search URL Search Domain Scan URL
Title: Vigil raises $90M in neuroscience 'renaissance.' Is an IPO around the corner?
Search URL Search Domain Scan URL
Title: shop.willowpump.com
Search URL Search Domain Scan URL
Title: Willow Innovations, Inc. Launches "Register for More" Campaign; Enlists Comedian and New Mom Iliza Shlesinger to Create its First TV Ad
Search URL Search Domain Scan URL
Title: Willow® Expands Product Suite and Unveils Willow Go™, Its Fully In-Bra Wearable Breast Pump for Only $329
Search URL Search Domain Scan URL
Title: Willow® Introduces the Perfect Pumping Bra to Give Moms Ultimate Support When Pumping with Willow
Search URL Search Domain Scan URL
Title: Willow Pump CEO Laura Chambers Wants to Bring Dignity Back to Breastfeeding
Search URL Search Domain Scan URL
Title: Going for the Liquid Gold: Willow Sends Breast Pumps to Olympic Athletes
Search URL Search Domain Scan URL
Title: Willow® Launches New Sizing Inserts To Reach More Moms
Search URL Search Domain Scan URL
Title: Breast pump innovator Willow gets additional $26.8 million in funding
Search URL Search Domain Scan URL
Title: Willow Gears Up for Massive Growth In 2021 with Three Strategic Hires
Search URL Search Domain Scan URL
Title: Willow® Partners with The Motherly Shop to Expand Its DTC Offerings
Search URL Search Domain Scan URL
Title: Willow, the startup making the wearable breast pump, raises $55 million
Search URL Search Domain Scan URL
Title: Breast pump startup Willow's new CEO, Laura Chambers, on innovation for women and mothers
Search URL Search Domain Scan URL
Title: How Airbnb exec Laura Chambers landed her first CEO job at femtech startup Willow just as the pandemic hit
Search URL Search Domain Scan URL
Title: An ER doctor who's a new mother shares what it's like to pump milk at work while risking exposure to coronavirus
Search URL Search Domain Scan URL
Title: Willow® Partners with Aeroflow Breastpumps to Offer Its Life-Changing Wearable Breast Pump Through Insurance
Search URL Search Domain Scan URL
Title: Willow's hidden breast pump changed my life at CES
Search URL Search Domain Scan URL
Title: Willow is about to launch its smartest breast pump yet—and it promises more milk + comfort
Search URL Search Domain Scan URL
Title: Willow’s Newest Pump Promises To Be Quiet & Efficient — First Look
Search URL Search Domain Scan URL
Title: Mom Breast Pumps While Running the New York City Marathon: 'Anything Is Possible'
Search URL Search Domain Scan URL
Title: Willow unveils a new version of its smart breast pump
Search URL Search Domain Scan URL
Title: Willow Named TIME Magazine 2017 Best Inventions
Search URL Search Domain Scan URL
Title: One Tech Company’s Revolutionary Idea: Design For Mothers First
Search URL Search Domain Scan URL
Title: The Willow could be the iPhone of breast pumps
Search URL Search Domain Scan URL
Title: Willow's smart breast pumps slide into moms' bras
Search URL Search Domain Scan URL
Title: coolsculpting.com
Search URL Search Domain Scan URL
Title: ClavystBio launches to translate life sciences breakthroughs into health impact
Search URL Search Domain Scan URL
Title: ProVerum Raises €30M in Series A Funding Led by Gilde Healthcare & Lightstone Ventures
Search URL Search Domain Scan URL
Title: Lightstone Ventures unveils $375M third fund, this time expanding its wishlist in blossoming CNS field
Search URL Search Domain Scan URL
Title: After 3 big exits, Lightstone snags largest fund yet with $375M geared toward next biotechs, medtechs
Search URL Search Domain Scan URL
Title: Lightstone Ventures Raises $375 Million Fund
Search URL Search Domain Scan URL
Title: Lightstone Ventures’ raises $375M for its largest fund yet
Search URL Search Domain Scan URL
Title: Medicare Proposal Could Spur Medical-Device Investment
Search URL Search Domain Scan URL
Title: MedTech Strategist Innovation Summit San Francisco 2019
Search URL Search Domain Scan URL
Title: 12 VCs who matter in biotech, but you hardly ever read about
Search URL Search Domain Scan URL
Title: Professor Dario Campana wins prestigious Gabbay Award
Search URL Search Domain Scan URL
Title: MedTech Strategist Innovation Summit Dublin 2019
Search URL Search Domain Scan URL
Title: Stanford/NVCA Venture Capital Symposium
Search URL Search Domain Scan URL
Title: 12 VCs who matter in biotech, but you never read about
Search URL Search Domain Scan URL
Title: Lightstone Ventures Closes New Life Sciences Fund at $250 Million
Search URL Search Domain Scan URL
Title: Biotech sector poised to deliver more health and wealth
Search URL Search Domain Scan URL
Title: Foundry SING1 Launches, Targets Asian Clinical Needs
Search URL Search Domain Scan URL
Title: Is Med Tech Venture Investment Waning?
Search URL Search Domain Scan URL
Title: Finishing Strong in 2016: NVCA Policy Victories in the Last Few Weeks
Search URL Search Domain Scan URL
Title: MINNEAPOLIS: Venture firm Lightstone taps med exec as partner
Search URL Search Domain Scan URL
Title: Lightstone Ventures Names Stacy Enxing Seng as Venture Partner
Search URL Search Domain Scan URL
Title: New life sciences fund gets $71m boost
Search URL Search Domain Scan URL
Title: Experienced med tech investor Lightstone Ventures closes $50M Singapore fund
Search URL Search Domain Scan URL
Title: Promise of new non-addictive painkillers to address opiate crisis highlighted in panel
Search URL Search Domain Scan URL
Title: FierceMedicalDevices’ 2015 Fierce 15
Search URL Search Domain Scan URL
Title: Lightstone’s Lettmann Finding Opportunities in Ireland
Search URL Search Domain Scan URL
Title: Addressing the challenges in medical innovation: VCJ
Search URL Search Domain Scan URL
Title: NVCA Members Testify at Congressional Hearing on Incentives to Advance Medical Research and Development
Search URL Search Domain Scan URL
Title: New €125m fund to boost innovative firms
Search URL Search Domain Scan URL
Title: VC Lightstone lands $172M fund with an eye on biotech startups
Search URL Search Domain Scan URL
Title: Susan Molineaux – FierceBiotech’s 2011 Women in Biotech
Search URL Search Domain Scan URL
Title: The Top Life Sciences Investors Of 2014
Search URL Search Domain Scan URL
Title: ‘We Need More Women In Venture Capital’ Say Female Midas Listers
Search URL Search Domain Scan URL
Title: Covidien, NEA and Lightstone are backing a stealthy Irish med tech startup
Search URL Search Domain Scan URL
Title: View Map
Search URL Search Domain Scan URL
Title: View Map
Search URL Search Domain Scan URL
Title: View Map
Search URL Search Domain Scan URL
Title: View Map
Search URL Search Domain Scan URL
Title: https://nvca.org/nvca-and-venture-forward-vchumancapital-pledge
Search URL Search Domain Scan URL
Page URL History
This captures the URL locations of the websites, including HTTP redirects and client-side redirects via JavaScript or Meta fields.
-
http://www.lightstonevc.com/
HTTP 301
https://www.lightstonevc.com/ Page URL
Redirected requests
There were HTTP redirect chains for the following requests:
Request Chain 67- https://googleads.g.doubleclick.net/pagead/id HTTP 302
- https://googleads.g.doubleclick.net/pagead/id?slf_rd=1
83 HTTP transactions
Method Protocol |
Resource Path |
Size x-fer |
Type MIME-Type |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GET H2 |
Primary Request
/
www.lightstonevc.com/ Redirect Chain
|
535 KB 538 KB |
Document
text/html |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
Redirect headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
js
www.googletagmanager.com/gtag/ |
106 KB 42 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
css
fonts.googleapis.com/ |
1023 B 930 B |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
wp-emoji-release.min.js
www.lightstonevc.com/wp-includes/js/ |
18 KB 18 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
grid.css
www.lightstonevc.com/wp-content/themes/enfold/css/ |
9 KB 9 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
base.css
www.lightstonevc.com/wp-content/themes/enfold/css/ |
19 KB 19 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
layout.css
www.lightstonevc.com/wp-content/themes/enfold/css/ |
78 KB 79 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
blog.css
www.lightstonevc.com/wp-content/themes/enfold/config-templatebuilder/avia-shortcodes/blog/ |
22 KB 22 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
postslider.css
www.lightstonevc.com/wp-content/themes/enfold/config-templatebuilder/avia-shortcodes/postslider/ |
4 KB 4 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
buttons.css
www.lightstonevc.com/wp-content/themes/enfold/config-templatebuilder/avia-shortcodes/buttons/ |
5 KB 5 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
comments.css
www.lightstonevc.com/wp-content/themes/enfold/config-templatebuilder/avia-shortcodes/comments/ |
6 KB 6 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
gallery.css
www.lightstonevc.com/wp-content/themes/enfold/config-templatebuilder/avia-shortcodes/gallery/ |
2 KB 2 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
grid_row.css
www.lightstonevc.com/wp-content/themes/enfold/config-templatebuilder/avia-shortcodes/grid_row/ |
1 KB 1 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
heading.css
www.lightstonevc.com/wp-content/themes/enfold/config-templatebuilder/avia-shortcodes/heading/ |
3 KB 3 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
hr.css
www.lightstonevc.com/wp-content/themes/enfold/config-templatebuilder/avia-shortcodes/hr/ |
2 KB 2 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
slideshow_layerslider.css
www.lightstonevc.com/wp-content/themes/enfold/config-templatebuilder/avia-shortcodes/slideshow_layerslider/ |
5 KB 5 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
social_share.css
www.lightstonevc.com/wp-content/themes/enfold/config-templatebuilder/avia-shortcodes/social_share/ |
1 KB 1 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
video.css
www.lightstonevc.com/wp-content/themes/enfold/config-templatebuilder/avia-shortcodes/video/ |
2 KB 2 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
style.min.css
www.lightstonevc.com/wp-includes/css/dist/block-library/ |
87 KB 88 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
slick.css
www.lightstonevc.com/wp-content/themes/enfold-child/js/slick/ |
2 KB 2 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
shortcodes.css
www.lightstonevc.com/wp-content/themes/enfold/css/ |
31 KB 31 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
magnific-popup.css
www.lightstonevc.com/wp-content/themes/enfold/js/aviapopup/ |
7 KB 7 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
avia-snippet-lightbox.css
www.lightstonevc.com/wp-content/themes/enfold/css/ |
4 KB 4 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
avia-snippet-site-preloader.css
www.lightstonevc.com/wp-content/themes/enfold/css/ |
2 KB 2 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
avia-snippet-widget.css
www.lightstonevc.com/wp-content/themes/enfold/css/ |
23 KB 24 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
mediaelementplayer-legacy.min.css
www.lightstonevc.com/wp-includes/js/mediaelement/ |
11 KB 11 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
wp-mediaelement.min.css
www.lightstonevc.com/wp-includes/js/mediaelement/ |
4 KB 4 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
enfold_child.css
www.lightstonevc.com/wp-content/uploads/dynamic_avia/ |
159 KB 161 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
custom.css
www.lightstonevc.com/wp-content/themes/enfold/css/ |
707 B 740 B |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
style.css
www.lightstonevc.com/wp-content/themes/enfold-child/ |
20 KB 20 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
jquery.fancybox.min.css
www.lightstonevc.com/wp-content/plugins/easy-fancybox/css/ |
4 KB 4 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
jquery.min.js
www.lightstonevc.com/wp-includes/js/jquery/ |
87 KB 88 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
jquery-migrate.min.js
www.lightstonevc.com/wp-includes/js/jquery/ |
11 KB 11 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
frontend-gtag.min.js
www.lightstonevc.com/wp-content/plugins/google-analytics-for-wordpress/assets/js/ |
12 KB 12 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
css
fonts.googleapis.com/ |
3 KB 526 B |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
Lightstone_Logo-512w.png
www.lightstonevc.com/wp-content/uploads/ |
15 KB 15 KB |
Image
image/png |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
analytics.js
www.google-analytics.com/ |
49 KB 20 KB |
Script
text/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
7Auwp_0qiz-afTLGLQ.woff2
fonts.gstatic.com/s/muli/v28/ |
30 KB 31 KB |
Font
font/woff2 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H3 |
linkid.js
www.google-analytics.com/plugins/ua/ |
2 KB 884 B |
Script
text/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
POST H3 |
collect
www.google-analytics.com/j/ |
2 B 22 B |
XHR
text/plain |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
POST H2 |
collect
stats.g.doubleclick.net/j/ |
1 B 443 B |
XHR
text/plain |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
portfolio_acceleron.png
www.lightstonevc.com/wp-content/uploads/ |
6 KB 6 KB |
Image
image/png |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
hero-1500.png
www.lightstonevc.com/wp-content/uploads/ |
282 KB 282 KB |
Image
image/png |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
microscope-1500.jpg
www.lightstonevc.com/wp-content/uploads/ |
132 KB 132 KB |
Image
image/jpeg |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
about-back-1500.png
www.lightstonevc.com/wp-content/uploads/ |
79 KB 79 KB |
Image
image/png |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
news-back-1500b.jpg
www.lightstonevc.com/wp-content/uploads/ |
8 KB 8 KB |
Image
image/jpeg |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
entypo-fontello.woff
www.lightstonevc.com/wp-content/themes/enfold/config-templatebuilder/avia-template-builder/assets/fonts/ |
30 KB 30 KB |
Font
font/woff |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
Lightstone_Icon-194w-120x120.png
www.lightstonevc.com/wp-content/uploads/ |
7 KB 7 KB |
Image
image/png |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
Diversity.png
www.lightstonevc.com/wp-content/themes/enfold-child/ |
174 KB 174 KB |
Image
image/png |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
slick.min.js
www.lightstonevc.com/wp-content/themes/enfold-child/js/slick/ |
42 KB 42 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
mediaelement-and-player.min.js
www.lightstonevc.com/wp-includes/js/mediaelement/ |
154 KB 154 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
mediaelement-migrate.min.js
www.lightstonevc.com/wp-includes/js/mediaelement/ |
1 KB 1 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
wp-mediaelement.min.js
www.lightstonevc.com/wp-includes/js/mediaelement/ |
906 B 962 B |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
jquery.fancybox.min.js
www.lightstonevc.com/wp-content/plugins/easy-fancybox/js/ |
19 KB 19 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
jquery.mousewheel.min.js
www.lightstonevc.com/wp-content/plugins/easy-fancybox/js/ |
3 KB 3 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
avia-footer-scripts-67ee4df617c3816ca23321107dadfd84.js
www.lightstonevc.com/wp-content/uploads/dynamic_avia/ |
99 KB 99 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H3 |
js
www.googletagmanager.com/gtag/ |
106 KB 41 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H3 |
7Aulp_0qiz-aVz7u3PJLcUMYOFnOkEk30eg.woff2
fonts.gstatic.com/s/muli/v28/ |
17 KB 17 KB |
Font
font/woff2 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
ptFE03h7KfE
www.youtube.com/embed/ Frame 95E0 |
0 0 |
Document
text/html |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H3 |
js
www.googletagmanager.com/gtag/ |
106 KB 41 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
POST H3 |
collect
www.google-analytics.com/j/ |
1 B 21 B |
XHR
text/plain |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H3 |
ptFE03h7KfE
www.youtube.com/embed/ Frame 95E0 |
70 KB 28 KB |
Document
text/html |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H3 |
www-player.css
www.youtube.com/s/player/1f77e565/ Frame 95E0 |
359 KB 49 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H3 |
www-embed-player.js
www.youtube.com/s/player/1f77e565/www-embed-player.vflset/ Frame 95E0 |
306 KB 95 KB |
Script
text/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H3 |
base.js
www.youtube.com/s/player/1f77e565/player_ias.vflset/de_DE/ Frame 95E0 |
2 MB 583 KB |
Script
text/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H3 |
fetch-polyfill.js
www.youtube.com/s/player/1f77e565/fetch-polyfill.vflset/ Frame 95E0 |
9 KB 3 KB |
Script
text/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H3 |
KFOmCnqEu92Fr1Mu4mxK.woff2
fonts.gstatic.com/s/roboto/v18/ Frame 95E0 |
15 KB 15 KB |
Font
font/woff2 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H3 |
KFOlCnqEu92Fr1MmEU9fBBc4.woff2
fonts.gstatic.com/s/roboto/v18/ Frame 95E0 |
15 KB 15 KB |
Font
font/woff2 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H3 |
id
googleads.g.doubleclick.net/pagead/ Frame 95E0 Redirect Chain
|
100 B 146 B |
XHR
application/json |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
Redirect headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
ad_status.js
static.doubleclick.net/instream/ Frame 95E0 |
29 B 588 B |
Script
text/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
OPTIONS H2 |
Create
jnn-pa.googleapis.com/$rpc/google.internal.waa.v1.Waa/ Frame |
0 0 |
Preflight
text/html |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
POST H3 |
Create
jnn-pa.googleapis.com/$rpc/google.internal.waa.v1.Waa/ Frame 95E0 |
66 KB 30 KB |
XHR
application/json+protobuf |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H3 |
remote.js
www.youtube.com/s/player/1f77e565/player_ias.vflset/de_DE/ Frame 95E0 |
118 KB 36 KB |
Script
text/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
zVL0qRr3dbQ5f-Xr-uvCrkOcgLrlGoDuIshvtmLe0dw.js
www.google.com/js/th/ Frame 95E0 |
36 KB 15 KB |
Script
text/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H3 |
embed.js
www.youtube.com/s/player/1f77e565/player_ias.vflset/de_DE/ Frame 95E0 |
25 KB 8 KB |
Script
text/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET DATA |
truncated
/ Frame 95E0 |
175 B 0 |
Image
image/png |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
SY88RyJlpbrF_-7SXSG62lZvM0htot-HV17L6mJMjzOhG3nOKQXTDT_6B6Ix0d2D6pn-WRTo7g=s68-c-k-c0x00ffffff-no-rj
yt3.ggpht.com/ Frame 95E0 |
3 KB 3 KB |
Image
image/jpeg |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
maxresdefault.webp
i.ytimg.com/vi_webp/ptFE03h7KfE/ Frame 95E0 |
33 KB 34 KB |
Image
image/webp |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H2 |
cast_sender.js
www.gstatic.com/cv/js/sender/v1/ Frame 95E0 |
4 KB 3 KB |
Script
text/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H3 |
generate_204
www.youtube.com/ Frame 95E0 |
0 10 B |
Image
text/plain |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GET H3 |
cast_sender.js
www.gstatic.com/eureka/clank/106/ Frame 95E0 |
52 KB 15 KB |
Script
text/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
POST H3 |
GenerateIT
jnn-pa.googleapis.com/$rpc/google.internal.waa.v1.Waa/ Frame 95E0 |
90 B 134 B |
XHR
application/json+protobuf |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
OPTIONS H3 |
GenerateIT
jnn-pa.googleapis.com/$rpc/google.internal.waa.v1.Waa/ Frame |
0 0 |
Preflight
text/html |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
POST H3 |
log_event
www.youtube.com/youtubei/v1/ Frame 95E0 |
28 B 54 B |
XHR
application/json |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General
Request headers
Response headers
|
Verdicts & Comments Add Verdict or Comment
80 JavaScript Global Variables
These are the non-standard "global" variables defined on the window object. These can be helpful in identifying possible client-side frameworks and code.
object| 0 object| onbeforeinput object| oncontextlost object| oncontextrestored function| structuredClone object| launchQueue object| onbeforematch function| getScreenDetails function| queryLocalFonts object| navigation string| mi_version boolean| mi_track_user string| mi_no_track_reason object| disableStrs function| __gtagTrackerIsOptedOut undefined| index function| __gtagTrackerOptout function| gaOptout function| __gtagDataLayer function| __gtagTracker object| dataLayer object| MonsterInsightsDualTracker function| gtag function| __gaTracker object| _wpemojiSettings object| google_tag_manager object| google_tag_data string| GoogleAnalyticsObject function| ga undefined| $ function| jQuery function| MonsterInsights object| MonsterInsightsObject object| monsterinsights_frontend boolean| avia_is_mobile object| gaplugins object| gaGlobal object| gaData object| twemoji object| wp function| changeNewsType function| changeNewsYear object| avia_framework_globals object| mejsL10n object| mejs function| MediaElement object| HtmlMediaElement function| onYouTubePlayerAPIReady function| DefaultPlayer function| MediaElementPlayer object| _wpmejsSettings function| _abort function| _error function| _start function| _process_inline function| _process_image function| _show function| _format_title function| _process_title function| _set_navigation function| _finish function| _preload_next function| _preload_prev function| _preload_image function| _draw function| _get_viewport function| _get_zoom_to function| _get_obj_pos function| _get_zoom_from function| _animate_loading undefined| fb_timeout object| fb_opts function| easy_fancybox_handler function| easy_fancybox_auto function| Froogaloop function| Waypoint function| onYouTubeIframeAPIReady function| $f number| news_item_total_count number| news_item_show_count6 Cookies
Cookies are little pieces of information stored in the browser of a user. Whenever a user visits the site again, he will also send his cookie values, thus allowing the website to re-identify him even if he changed locations. This is how permanent logins work.
Domain/Path | Expires | Name / Value |
---|---|---|
.lightstonevc.com/ | Name: _ga Value: GA1.2.375947915.1666027709 |
|
.lightstonevc.com/ | Name: _gid Value: GA1.2.1348083232.1666027709 |
|
.lightstonevc.com/ | Name: _gat_gtag_UA_158195753_1 Value: 1 |
|
.lightstonevc.com/ | Name: _gat_gtag_UA_28330657_1 Value: 1 |
|
.youtube.com/ | Name: YSC Value: jRKtd3SzWYA |
|
.youtube.com/ | Name: VISITOR_INFO1_LIVE Value: RpbqMkiAAl0 |
Indicators
This is a term in the security industry to describe indicators such as IPs, Domains, Hashes, etc. This does not imply that any of these indicate malicious activity.
fonts.googleapis.com
fonts.gstatic.com
googleads.g.doubleclick.net
i.ytimg.com
jnn-pa.googleapis.com
static.doubleclick.net
stats.g.doubleclick.net
www.google-analytics.com
www.google.com
www.googletagmanager.com
www.gstatic.com
www.lightstonevc.com
www.youtube.com
yt3.ggpht.com
173.199.178.36
2a00:1450:4001:810::2003
2a00:1450:4001:812::2016
2a00:1450:4001:827::2002
2a00:1450:4001:827::200a
2a00:1450:4001:827::200e
2a00:1450:4001:828::2001
2a00:1450:4001:82a::2003
2a00:1450:4001:82a::2006
2a00:1450:4001:82b::2008
2a00:1450:4001:82b::200a
2a00:1450:4001:830::2004
2a00:1450:4001:831::200e
2a00:1450:400c:c07::9b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